InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,627.84
(
0.03%
)
US TECH 100
18,874.20
(
-0.73%
)
Dow Jones
41,570.99
(
0.43%
)
Brent Oil
72.50
(
1.55%
)
Bitcoin
57,651.65
(
-2.58%
)
Post# of 253127
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 47
Posts 4683
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: dewophile post# 243595

Friday, 08/26/2022 1:41:37 PM

Friday, August 26, 2022 1:41:37 PM

Post# of 253127

the JNJ data from a pretty large phase 2 that showed 80 percent efficacy for severe disease and 70 for milder lower respiratory tract disease.



minor correction JNJ showed 75% efficacy for milder pneumonia based on the same definition PFE used. I think given the number of events and wide confidence intervals it is all noise and the PFE data stack up to the JNJ just fine (without the clotting risk that may dog the JNJ vax commercially)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up